Literature DB >> 23228414

QSAR studies of macrocyclic diterpenes with P-glycoprotein inhibitory activity.

Inês J Sousa1, Maria-José U Ferreira2, Joseph Molnár3, Miguel X Fernandes4.   

Abstract

Multidrug resistance (MDR) represents a major limitation for cancer chemotherapy. There are several mechanisms of MDR but the most important is associated with P-glycoprotein (P-gp) overexpression. The development of modulators of P-gp that are able to re-establish drug sensitivity of resistant cells has been considered a promising approach for overcoming MDR. Macrocyclic lathyrane and jatrophane-type diterpenes from Euphorbia species were found to be strong MDR reversing agents. In this study we applied quantitative structure-activity relationship (QSAR) methodology in order to identify the most relevant molecular features of macrocyclic diterpenes with P-gp inhibitory activity and to determine which structural modifications can be performed to improve their activity. Using experimental biological data at two concentrations (4 and 40 μg/ml), we developed a QSAR model for a set of 51 bioactive diterpenic compounds which includes lathyrane and jatrophane-type diterpenes and another model just for jatrophanes. The cross-validation correlation values for all diterpenes QSAR models developed for biological activities at compound concentrations of 4 and 40 μg/ml were 0.758 and 0.729, respectively. Regarding the prediction ability, we get R²(pred) values of 0.765 and 0.534 for biological activities at compound concentrations of 4 and 40 μg/ml, respectively. Applying the cross-validation test to jatrophanes QSAR models, we obtained 0.680 and 0.787 for biological activities at compound concentrations of 4 and 40 μg/ml concentrations, respectively. For the same concentrations, the obtained R²(pred) values for jatrophanes models were 0.541 and 0.534, respectively. The obtained models were statistically valid and showed high prediction ability.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23228414     DOI: 10.1016/j.ejps.2012.11.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and drug-bank compounds.

Authors:  Trieu-Du Ngo; Thanh-Dao Tran; Minh-Tri Le; Khac-Minh Thai
Journal:  Mol Divers       Date:  2016-07-18       Impact factor: 2.943

2.  Structure Identification and In Vitro Anticancer Activity of Lathyrol-3-phenylacetate-5,15-diacetate.

Authors:  Jian-Ye Zhang; Wen-Jing Huang; Hong-Mei Sun; Yun Liu; Xiao-Qin Zhao; Si-Li Tang; Ming-Na Sun; Sheng Wang; Jia-Jun Li; Ling-Ling Zhang; Jun-Hua Zhou; Qian-Rong Pan; Hu-Biao Chen
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

3.  Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer.

Authors:  Mariana Alves Reis; Ana M Matos; Noélia Duarte; Omar Bauomy Ahmed; Ricardo J Ferreira; Hermann Lage; Maria-José U Ferreira
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

Review 4.  Pharmacological Potential of Lathyrane-Type Diterpenoids from Phytochemical Sources.

Authors:  Fátima Vela; Abdellah Ezzanad; Alan Christy Hunter; Antonio José Macías-Sánchez; Rosario Hernández-Galán
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-23

5.  3D-QSAR modelling dataset of bioflavonoids for predicting the potential modulatory effect on P-glycoprotein activity.

Authors:  Pathomwat Wongrattanakamon; Vannajan Sanghiran Lee; Piyarat Nimmanpipug; Supat Jiranusornkul
Journal:  Data Brief       Date:  2016-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.